Alicia Leiva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alicia Leiva has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Aina Soler
Primary Care Research Unit of Mallorca, Baleares Health Services-IbSalut, Palma, Spain.
1 shared publication - Alfonso Leiva
Primary Care Research Unit of Mallorca, Baleares Health Services-Ibsalut, Palma, Spain
1 shared publication - Fabrice B. R. Parmentier
University of the Balearic Islands
1 shared publication - Guillem Amer
Son Espases Hospital, Baleares Health Services-IbSalut, Palma, Spain
1 shared publication - Joan Llobera
Primary Care Research Unit of Mallorca, Balearic Islands Health Service, Palma, Spain
1 shared publication - Joana Maria Taltavull
Primary Health Care Service in the Majorca Island, Balearic Regional Health Service, 07003 Palma, Spain
1 shared publication
Latest Publications
- Open Access
- 11 April 2019
- Published by Springer Nature in BMC Geriatrics
- Vol. 19 (1) , 101
Continuation versus discontinuation of treatment for severe dementia: randomized, pragmatic, open-label, clinical trial to evaluate the efficacy of continuing drug treatment in patients with severe dementia (STOP-DEM)
Previous observational studies and clinical trials have shown that cholinesterase inhibitors (with or without memantine) provide benefit for patients with mild-to-moderate Alzheimer’s disease. However, the impact of treatment continuation after progression to severe disease is unknown. The main aim of this study is to evaluate the effect and safety of continuing treatment with ChEIs (with or without memantine) for patients with severe dementia. This randomized, pragmatic, open-label clinical trial with blinded evaluators will evaluate the efficacy of continuing drug treatment in patients with advanced dementia. A total of 302 community-dwelling patients with severe dementia, Alzheimer’s disease, with or without a coexisting diagnosis of vascular dementia, and a score of 10 or less on the Mini-Mental State Examination who received previous treatment with a cholinesterase inhibitor (with or without memantine) for at least 3 months, will be randomized to continue or discontinue drug treatment. Follow-up will be 12 months or until the primary endpoint is achieved. The primary endpoint is entry into institutional care and progression of disability, defined as a loss of 2 of 4 basic functions, or 6 of 11 instrumental functions, according to the Bristol Activities of Daily Living Scale at 12 months. The secondary outcomes are patient changes in functional and cognitive state, quality of life, and caregiver burden. We expect that the results of our study will allow to identify if there is clinical relevant impact for patients and caregivers between maintaining or halting pharmacological treatment. The study was prospectively registered in the REec (2017–000042-22) on May 11 2017 and ID ISRCTN12134230 on February 25 2019.
- 11 April 2019
- Published by Springer Nature in BMC Geriatrics
- Vol. 19 (1) , 101
Open AccessContinuation versus discontinuation of treatment for severe dementia: randomized, pragmatic, open-label, clinical trial to evaluate the efficacy of continuing drug treatment in patients with severe dementia (STOP-DEM)
Previous observational studies and clinical trials have shown that cholinesterase inhibitors (with or without memantine) provide benefit for patients with mild-to-moderate Alzheimer’s disease. However, the impact of treatment continuation after progression to severe disease is unknown. The main aim of this study is to evaluate the effect and safety of continuing treatment with ChEIs (with or without memantine) for patients with severe dementia. This randomized, pragmatic, open-label clinical trial with blinded evaluators will evaluate the efficacy of continuing drug treatment in patients with advanced dementia. A total of 302 community-dwelling patients with severe dementia, Alzheimer’s disease, with or without a coexisting diagnosis of vascular dementia, and a score of 10 or less on the Mini-Mental State Examination who received previous treatment with a cholinesterase inhibitor (with or without memantine) for at least 3 months, will be randomized to continue or discontinue drug treatment. Follow-up will be 12 months or until the primary endpoint is achieved. The primary endpoint is entry into institutional care and progression of disability, defined as a loss of 2 of 4 basic functions, or 6 of 11 instrumental functions, according to the Bristol Activities of Daily Living Scale at 12 months. The secondary outcomes are patient changes in functional and cognitive state, quality of life, and caregiver burden. We expect that the results of our study will allow to identify if there is clinical relevant impact for patients and caregivers between maintaining or halting pharmacological treatment. The study was prospectively registered in the REec (2017–000042-22) on May 11 2017 and ID ISRCTN12134230 on February 25 2019.
- Open Access
- 1 January 2011
- Published by Frontiers Media SA in Frontiers in Human Neuroscience
- Vol. 5
The behavioral impact of auditory and visual oddball distracters in a visual and auditory categorization tasks
Past cross-modal oddball studies have shown that participants respond slower to visual targets following the presentation of an unexpected change in a stream of auditory distracters. In the present study we examined the extent to which this novelty distraction may transcend the sensory distinction between distracter and target. In separate blocks of trials, participants categorized digits presented auditorily or visually in the face of visual or auditory standard and oddball distracters. The results showed significant novelty distraction in the presence of auditory novel stimuli, irrespective of whether the targets were visual. Visual oddball distracters yielded no distraction, however, whether targets were visual or auditory. The results therefore suggest that novelty distraction was not mediated by the sensory modality of the target stimuli but by that of the distracter. Funding: Supported by the Spanish Ministry of Science and Innovation (PSI2009-08427).
- 1 January 2011
- Published by Frontiers Media SA in Frontiers in Human Neuroscience
- Vol. 5
Open AccessThe behavioral impact of auditory and visual oddball distracters in a visual and auditory categorization tasks
Past cross-modal oddball studies have shown that participants respond slower to visual targets following the presentation of an unexpected change in a stream of auditory distracters. In the present study we examined the extent to which this novelty distraction may transcend the sensory distinction between distracter and target. In separate blocks of trials, participants categorized digits presented auditorily or visually in the face of visual or auditory standard and oddball distracters. The results showed significant novelty distraction in the presence of auditory novel stimuli, irrespective of whether the targets were visual. Visual oddball distracters yielded no distraction, however, whether targets were visual or auditory. The results therefore suggest that novelty distraction was not mediated by the sensory modality of the target stimuli but by that of the distracter. Funding: Supported by the Spanish Ministry of Science and Innovation (PSI2009-08427).